Patricia Weiser, PharmD

The vaccine showed an overall efficacy of 80% in the per-protocol analysis, with a risk reduction of 6.1 typhoid infections per 1000 vaccinated children.

Study authors noted that intranasal vaccine delivery could offer benefits such as needle-free administration and induction of mucosal immunity.

Vaccinated study participants experienced fewer and less persistent symptoms, as well as fewer work hours lost, compared to unvaccinated participants.

Researchers concluded that older patients with stable MS can stop taking disease-modifying therapy because risk of relapse is so small.

The frequency of drug manufacturer coupon utilization is associated with more market competition—but not patients’ out-of-pocket costs.

The approval of Rinvoq (upadacitinib) was based on the results of three clinical trials: two induction therapy studies and one maintenance study.

Researchers found a significant decrease in mortality or discharge to hospice with the hydrocortisone-fludrocortisone combination versus hydrocortisone alone in septic shock cases.

Using a national database, data on medication purchases was collected, along with factors that may have influenced expenditures, such as new therapy availability, patent expirations, policy changes, and legislation.

A recent study found that Medicare patients used low-benefit options more frequently than high-benefit options.

The FDA is hoping these warnings are a positive step in what will be an extremely long process of ending opioid related deaths.

Tirzepatide was associated with a greater reduction in hemoglobin A1c and body weight when compared to semaglutide. But with a current list price of $1,023 for a one-month supply, is tirzepatide (Mounjaro; Lilly) worth it?

The FDA granted the EUA based on the phase 3 trial results that demonstrated vilobelimab's efficacy compared to placebo, with a 23.9% relative reduction in all-cause mortality from COVID-19 at 28 days.